ORKA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -5.47%, SMA50 -3.93%, SMA200 55.3%). The stock’s 14-day RSI is 45.82 (neutral), while the ATR of 2.01 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.64% below its high and over 407.93% above its low. Average 10-day trading volume of 524.18 thousand shares is in line with the 3-month average of 518.31 thousand, indicating normal recent market interest.

Oruka Therapeutics, Inc. last paid a dividend of 19.36 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.61. This means the shares are trading above this model’s fair value.

Oruka Therapeutics, Inc. has 37.45 million shares outstanding. The public float is 22.41 million shares, elevated short interest at 14.37% of float. This equals 3.36 million shares. The short ratio is 19.35 days. Institutional investors hold 96.9% of the float. Insiders own 3.82%. Venrock Healthcare Capital Partners III, L.P. holds 4.15 million shares, Sandler Laura Lee has 205.08 thousand shares and Goncalves Joana has 1.52 thousand shares. Over the past six months, insider transactions show net selling. They sold 4.19 thousand shares across 2 transactions.

Oruka Therapeutics, Inc. generated EPS of -$2.42 over the past year. Five-year average earnings growth is 36.88%. Wall Street analysts project EPS growth of 10.67% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 11 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $75.00 to $20.00. The high target offers 169.2% upside. The low target suggests -28.21% downside. The mean target is $49.57. This offers 77.93% upside. Oruka Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -1.79%. The prior quarter beat by -4.17%. Over the last six quarters, Apple has recorded several small beats. These include 200.0% in November 06, 2024.

Oruka Therapeutics, Inc. trades at a P/E ratio of -11.24, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.52 suggesting the stock is closer to book value. The P/FCF stands at -12.33, also above market averages.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares are down -12.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Oruka Therapeutics, Inc. trading at a premium to the broader market with a P/E of -11.24. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $47.76, suggesting 71.43% upside. Our AI forecast model points to short-term weakness (-11.02% over two weeks), a medium-term fall (-60.16% over three months), and a longer-term loss (-3.45% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Oruka Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.02%, with price expected at $24.79 by January 23, 2026, within a range of $23.38 to $26.16 3-Month Outlook: Projected fall of -60.16%, reaching $11.10 by April 09, 2026, with a range of $9.83 to $12.17. 1-Year Outlook: Projected loss of -3.45%, with price at $26.90 by December 31, 2026, within a range of $23.95 to $29.63.